Clinical characteristics of patients with bone sarcoidosis

被引:69
作者
Zhou, Ying [1 ,2 ]
Lower, Elyse E. [1 ]
Li, Huiping [2 ]
Farhey, Yolanda [1 ]
Baughman, Robert P. [1 ]
机构
[1] Univ Cincinnati, Dept Internal Med, Med Ctr, 1001 Holmes,Eden Ave, Cincinnati, OH 45267 USA
[2] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Resp Med, Shanghai, Peoples R China
关键词
Bone sarcoidosis; Infliximab; Methotrexate; Bone marrow; MARROW INVOLVEMENT; MRI;
D O I
10.1016/j.semarthrit.2017.02.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess the clinical features, diagnosis, and treatment of bone sarcoidosis in the United States. Methods: Patients with bone sarcoidosis were identified and matched to sarcoidosis patients based on race, gender, and age. Detailed characteristics were obtained by medical record review. Results: A total of 64 patients with bone sarcoidosis were enrolled in this study. The female:male ratio was 1.46:1 and the white:black ratio was 3:1. Thirty-eight (59.4%) of 64 patients had bone symptoms. Compared to matched cases, bone sarcoidosis patients have more multi-organ involvement and higher incidence with liver, spleen, and extrathoracic lymph node involvement than controls (P < 0.05). Spine was the most commonly affected bone in 44 (68.8%) of patients, followed by pelvis (35.9%), and hands (15.6%). MRI and PET/CT scan was the common imaging technology, which performed in 36 patients and 32 patients, respectively, and with 97.2% and 93.8% positive bone uptake. Laboratory test indicated anemia was more common in bone sarcoidosis group than controls (P = 0.044). Infliximab was more commonly used in bone sarcoidosis patients than controls (P = 0.009). Conclusion: Bone sarcoidosis was associated with multi-organs affection, and high frequency of liver, spleen, or extrathoracic lymph node involvement. Infliximab should be considered in those patients with aggressive and refractory bone sarcoidosis. (C) 2017 The Authors. Published by Elsevier HS Journals, Inc.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 18 条
[1]   New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches [J].
Baughman, Robert P. ;
Grutters, Jan C. .
LANCET RESPIRATORY MEDICINE, 2015, 3 (10) :813-822
[2]   Unsuspected Active Sarcoidosis Diagnosed by 18F-FDG PET/CT During the Search for a Primary Tumour in a Patient with Bone Lesions [J].
Caobelli F. ;
Gabanelli S.V. ;
Brucato A. ;
Pizzocaro C. ;
Soffientini A. ;
Giubbini R. ;
Guerra U.P. .
Nuclear Medicine and Molecular Imaging, 2013, 47 (3) :205-207
[3]   Sarcoidosis with bone involvement mimicking metastatic disease at F-18-FDG PET/CT: problem solving by diffusion whole-body MRI [J].
Conte, Giorgio ;
Zugni, Fabio ;
Colleoni, Marco ;
Renne, Giuseppe ;
Bellomi, Massimo ;
Petralia, Giuseppe .
ECANCERMEDICALSCIENCE, 2015, 9
[4]   Refractory vertebral sarcoidosis responding to infliximab [J].
Garg, Sanjay ;
Garg, Kusum ;
Altaf, Mujeeb ;
Magaldi, John A. .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2008, 14 (04) :238-240
[5]   Osseous Sarcoidosis Treated With Tumor Necrosis Factor-Inhibitors Case Report and Review of the Literature [J].
Hasni, Sarfaraz A. ;
Kunz, Daniel ;
Finzel, Kathleen ;
Gruber, Barry L. .
SPINE, 2010, 35 (18) :E904-E907
[6]   Explaining sarcoidosis of bone [J].
Heffher, Dennis K. .
ANNALS OF DIAGNOSTIC PATHOLOGY, 2007, 11 (06) :464-469
[7]  
Hunninghake GW, 1999, AM J RESP CRIT CARE, V160, P736
[8]  
Judson MA, 2014, SARCOIDOSIS VASC DIF, V31, P19
[9]  
Kalajian AH, 2009, ARCH DERMATOL, V145, P905, DOI 10.1001/archdermatol.2009.75
[10]   Can Sarcoidosis and Metastatic Bone Lesions Be Reliably Differentiated on Routine MRI? [J].
Moore, Sandra Leigh ;
Kransdorf, Mark J. ;
Schweitzer, Mark E. ;
Murphey, Mark D. ;
Babb, James S. .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2012, 198 (06) :1387-1393